Key Takeaways
- Rare disease commercial models start with the patient journey—not the organizational chart.
- Map entry points, diagnostic delay, referral triggers and treatment initiation barriers.
- Centers of Excellence and advocacy networks often sit inside the journey, not outside it.
- Journey insights should shape Medical Affairs, access, field focus and organization design.
Rare disease commercialization should begin with a simple discipline: understand how patients actually move through the healthcare system.
Prevalence estimates create a headline. The patient journey creates the commercial model. In my experience, companies that skip this work often overstate near-term opportunity and underinvest where patients are lost.
This work sits at the center of rare disease commercialization consulting.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
